Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 Post author:Sam Post published:February 1, 2018 Post category:BioPharma Alder intends to use the cash to fund the development and commercialization of eptinezumab. Source: BioSpace You Might Also Like Why June Could be a Pivotal Month for These 2 Biotechs May 29, 2017 3 Biotechs Wall Street Predicts is Heading Toward Tremendous Growth April 2, 2017 13-Employee SoCal Startup Bioniz Has A $400 Million Valuation December 19, 2017